KLK3 and neoplasm: Previous studies have shown that 63% of patients treated with Ac-225-PSMA-617 achieved a decrease in prostate-specific antigen (PSA) of>50% within 8 weeks of treatment, 87% of patients observed a degree of PSA remission, the median tumor control time was 9 months, and 5 patients had sustained remission for more than 2 years.